Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed to experimental motion

Next Previous
Trial Profile

A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed to experimental motion

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seliforant (Primary) ; Meclozine
  • Indications Vertigo
  • Focus Pharmacodynamics
  • Sponsors Sensorion

Most Recent Events

  • 12 May 2019 Status changed from active, no longer recruiting to completed.
  • 14 Dec 2018 Top-line results presented in a Sensorion media release.
  • 27 Nov 2018 According to a Sensorion media release, subject enrolment and dosing has been completed in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top